TrialThe Lancet. Respiratory medicine2025

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

Lorenzo Guglielmetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.